PreveCeutical Medical applies to acquire human tissue for next phase of Sol-gel technology testing

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) revealed that its Sol-gel drug delivery research and development (R&D) program is set to be boosted as it has applied to acquire human nasal tissue for the final phase of testing the technology.

The health sciences group is developing the first, sustained-release, CANNABIS and CBD-based nose-to-brain delivery system aimed at providing relief for pain, inflammation, seizures, and neurological disorders.

READ: PreveCeutical Medical appoints Dr Makarand Jawadekar as president

Sol-gels are taken via the nose and rapidly gel upon contact with mucosal tissue.

“This is an important next step for the Sol-gel Program,” said the company’s president and chief science officer Dr Mak Jawadeka in a statement.

“Having demonstrated, in an in-vitro model, using an adult human nasal cast, that the company’s CBD Sol-gel is delivered to and retained directly at target tissue high in the nasal cavity when administered with the Sol-gel applicator, we look forward to testing the Sol-gels on human nasal tissue. This will allow PreveCeutical to potentially deliver a host of therapeutics safely from nose-to-brain in a reliable and sustained manner, which remains a significant challenge for many companies, globally.”

Human ethics committee

The company said that Preveceutical’s research team at the University of Queensland had filed an application to a local hospital’s human ethics committee to acquire the tissue.

Preveceutical currently has five research and development programs.

These are for dual gene therapy for curative and prevention therapies for diabetes and obesity, the Sol-gel program, Nature Identical peptides for treatment of various ailments.

It is also advancing non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Contact Giles at [email protected]

Follow him on Twitter@Gile74

Story by ProactiveInvestors